02 - 20

Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases

Please click the following link for access to the publication

https://doi.org/10.1038/s41423-020-0381-3

or download the publication as a PDF document (20mb combined)

Share on social media:

Other news

06-26

Exploring the Emerging Role of Extracellular Traps in Immune-Mediated Inflammatory Diseases

Earlier this week, Citryll hosted an educational webinar bringing together leading scientific and clinical experts to discuss the evolving understanding

04-26

Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013

Expected to provide exclusivity into 2039 Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative

02-26

First patient dosed in Citryll’s imaging study evaluating distribution and target engagement of CIT-013

PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target disposition in participants

02-26

Employee Spotlight – Catarina Antunes

As a key part of Citryll’s team, Catarina Antunes, Program & Communications Manager, plays a central role in driving cross‑functional

12-25

End of Year Newsletter 2025

As I look back on 2025, it has been a truly remarkable year for the Citryll team. With a laser

12-25

First Patient Dosed In Citryll’s Phase IIA Hidradenitis Suppurativa Trial

Multi-center, randomized study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with hidradenitis suppurativa Marks the